Introduction: Studies on the association of preeclampsia (PE) with thrombophilias (TRPH) are conflicting. Clinical heterogeneity of PE may be one of the explanations.
Objectives: The present study addresses the question whether different phenotypes of PE are associated with subtypes of TRPH.
Methods: In this retrospective cohort study between 1985 until 2010 women with PE were offered postpartum screening for the following TRPH: anti-phospholipid antibodies (APA), APC-resistance, protein C deficiency and protein S deficiency (PSD), hyperhomocysteinemia (HCY), factor V Leiden and Prothrombin gene mutation.
Results: 890 Women with PE were screened for TRPH. 49% Also had HELLP, 60% had IUGR, 71% delivered before the 34th week. One or more TRPH factors were present in 31% of the women. Severe PE was associated with PSD (p=0.01). IUGR (p<0.01) was associated with APA (p<0.01) and PSD (P=0.03). Early onset PE was associated with APA (P, 0.01). More than 10% of placental infarction was associated with APA (p<0.01). Placental weight below the 5th percentile was associated with HCY (p=0.03). Other phenotypes of PE and TRPH were not associated.
Conclusion: Severe and early onset PE, especially if complicated by IUGR, are associated with APA and PSD. Other phenotypes of PE, especially HELLP syndrome, were not associated with TRPH. We advise to screen for APA and PSD after severe and early onset PE, especially if complicated by IUGR. We do not recommend screening for TRPH in other phenotypes of PE.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.preghy.2013.04.072 | DOI Listing |
Am J Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium. Electronic address:
Background: Aspirin has proved its efficacy in reducing the rate of preeclampsia in singleton pregnancy, however, there is discrepancy about the efficient dosage that should be used. While some societies recommend daily 75-81mg, others recommend higher dosage (160mg). This discrepancy is due to the lack of randomized controlled studies that compare these two dosages.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Obstetrics and Gynecology, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Pregnancy complications associated with thrombophilia represent significant risks for maternal and fetal health, leading to adverse outcomes such as pre-eclampsia, recurrent pregnancy loss, and intra-uterine growth restriction (IUGR). They are caused by disruptions in key physiological processes, including the coagulation cascade, trophoblast invasion, angiogenesis, and immune control. Recent advancements in epigenetics have revealed that non-coding RNAs, especially microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and extracellular vesicles (EVs) carrying these RNAs, play crucial roles in the regulation of these biological processes.
View Article and Find Full Text PDFJ Clin Med
December 2024
Division of Cardiology, Department of Medicine, NewYork-Presbyterian Hospital-Weill Cornell Medicine, New York, NY 10021, USA.
Thrombosis is an important cause of morbidity and mortality worldwide. Pregnancy is a hypercoagulable state, and thrombotic complications in pregnancy are a major cause of maternal and fetal morbidity and mortality. Current guidelines support the selective use of aspirin, heparin, and warfarin in pregnant women.
View Article and Find Full Text PDFJ Perinat Med
December 2024
Department of Obstetrics and Gynaecology, Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Objectives: This study aims to analyze the impact of COVID-19 on pregnancy and labor, focusing on its effects on maternal and child health. The research explores the relationships between coronavirus infection and clinical and laboratory parameters, as well as the risks of pregnancy complications and adverse birth outcomes.
Methods: The study involved 60 pregnant women diagnosed with COVID-19.
Am J Obstet Gynecol MFM
November 2024
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, MO (Burd and Zofkie).
Venous thromboembolism (VTE), a largely preventable condition, accounts for almost 15% of maternal mortalities. The physiologic changes of pregnancy, including quantitative changes in coagulation factors and compression of vasculature by the gravid uterus, cause an increase in risk of VTE, including deep vein thromboembolism (DVT), pulmonary embolism, and stroke (CVA). Long term antepartum admission for preeclampsia, preterm prelabor rupture of membranes (PPROM) or other high-risk pregnancy needs present additional risk factors for VTE due to the patient's medical condition and their inpatient status.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!